Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Current Deferred Revenue (2024 - 2025)

Kura Oncology (KURA) has disclosed Current Deferred Revenue for 2 consecutive years, with $49.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Current Deferred Revenue rose 101.82% to $49.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $49.0 million, a 101.82% increase, with the full-year FY2025 number at $49.0 million, up 101.82% from a year prior.
  • Current Deferred Revenue was $49.0 million for Q4 2025 at Kura Oncology, roughly flat from $48.8 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $49.4 million in Q2 2025 to a low of $24.3 million in Q4 2024.